Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Erlotinib hydrochloride
71
CHF
CHF 71.00
In stock
SYN-1039-M0011 mgCHF 71.00
SYN-1039-M0055 mgCHF 99.00
SYN-1039-M01010 mgCHF 128.00
SYN-1039-M05050 mgCHF 170.00
SYN-1039-M100100 mgCHF 206.00
Product Details | |
---|---|
Synonyms | OSI774; CP-358774; Tarceva; NSC718781 |
Product Type | Chemical |
Properties | |
Formula | C22H23N3O4 . HCl |
MW | 393.4 . 36.5 |
CAS | 183319-69-9 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: EGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | GTTBEUCJPZQMDZ-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
Erlotinib inhibits EGFR tyrosine kinase auto-phosphorylation. Studies in cell lines and enzyme assays have shown that erlotinib inhibits EGFR at concentrations significantly lower than those needed to inhibit c-src and v-abl. It has an IC(50) of 2nM against EGFR. It is >1000-fold more sensitive for EGFR than for c-Src or v-Abl.
Product References
- Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen: J.R. Johnson, et al.; Clin. Cancer Res. 11, 6414 (2005)